Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rotavirus Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

NCT06962904
View directory record Official record
Conditions
Rotavirus Infections
Interventions
3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo
Biological · Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules

NCT01266850
View directory record Official record
Conditions
Rotavirus Infection
Interventions
Rotarix®, RotaTeq®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Weeks to 14 Weeks
Enrollment
1,384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
13
States / cities
Oakland, California • Atlanta, Georgia • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00806195
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Biological
Lead sponsor
Novartis
Industry
Eligibility
55 Days to 89 Days
Enrollment
7,744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
130
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

NCT01049035
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 365 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study

NCT02542462
View directory record Official record
Conditions
Intussusception, Rotavirus Infections
Interventions
Rotarix®,, Rotarix®, with other routine vaccines, RotaTeq®,, RotaTeq®, with other routine vaccines
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
42 Days to 90 Days
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

NCT03207750
View directory record Official record
Conditions
Rotavirus Infection, Rotavirus Vaccines
Interventions
Rotarix, Pediarix, Hiberix, Prevenar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 4 Interventional

Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure

NCT00995813
View directory record Official record
Conditions
Intestinal Failure, Rotavirus Vaccines
Interventions
Rotarix
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Weeks to 14 Weeks
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 5, 2026, 2:25 AM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

NCT03537508
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children

NCT06038617
View directory record Official record
Conditions
Fever After Vaccination, Fever, Seizures Fever
Interventions
mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Months to 4 Years
Enrollment
347 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 5, 2026, 2:25 AM EDT
Completed No phase listed Observational Results available

Effectiveness of Monovalent Rotavirus Vaccine (RV1)

NCT01871038
View directory record Official record
Conditions
Rotavirus, Acute Gastroenteritis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 5 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA

NCT00334607
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
2-dose oral live attenuated G1P[8] human rotavirus vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 16 Weeks
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Benton, Arkansas • Cabot, Arkansas • Jonesboro, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03673462
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,797 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
67
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03691610
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 19 Months
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 5, 2026, 2:25 AM EDT
Completed No phase listed Observational

Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island

NCT01026779
View directory record Official record
Conditions
Rotavirus Gastroenteritis
Interventions
Not listed
Lead sponsor
Lifespan
Other
Eligibility
2 Months to 5 Years
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

NCT04398706
View directory record Official record
Conditions
Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Interventions
Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 15 Months
Enrollment
852 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
49
States / cities
Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine

NCT01764256
View directory record Official record
Conditions
Rotavirus Infection
Interventions
P2-VP8 subunit rotavirus vaccine, placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome

NCT00767364
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)
Biological
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
6 Weeks to 18 Months
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 5, 2026, 2:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States

NCT00875641
View directory record Official record
Conditions
Infections, Rotavirus
Interventions
Health Insurance Database
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 1 Year
Enrollment
390,659 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Probiotic Supplementation on Immune Function in Healthy Infants

NCT01542320
View directory record Official record
Conditions
Inflammation
Interventions
Lactobacillus reuteri DSM 17938, Placebo
Dietary Supplement · Other
Lead sponsor
Emory University
Other
Eligibility
6 Weeks to 32 Weeks
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

NCT03620162
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13™, V114, RotaTeq™, Pentacel™, RECOMBIVAX HB™, HIBERIX™, M-M-R™ II, VARIVAX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 5, 2026, 2:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)

NCT01960725
View directory record Official record
Conditions
Diarrhea, Gastroenteritis
Interventions
RV5 (Pentavalent Rotavirus Vaccine)
Biological
Lead sponsor
Dennis Clements
Other
Eligibility
14 Days to 83 Days
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 5, 2026, 2:25 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06397768
View directory record Official record
Conditions
RSV Immunization
Interventions
RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 12 Months
Enrollment
2,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 5, 2026, 2:25 AM EDT